Tag
HPV-positive keratinizing nasopharyngeal carcinoma demonstrates significantly improved overall survival compared to HPV-negative cases, underscoring the prognostic and clinical relevance of HPV testing in NPC management.
This study develops a surgical map delineating high-risk anatomical sites linked to poor local control in salvage endoscopic nasopharyngectomy, improving patient selection and oncologic outcomes in recurrent nasopharyngeal carcinoma.
This article critically appraises a multicenter study validating the Anti-BNLF2b antibody (P85-Ab) assay, highlighting its superior sensitivity and specificity for early nasopharyngeal carcinoma detection compared to established EBV-based b
In a prospective multicenter cohort, P85-Ab achieved 93.0% sensitivity and 97.3% specificity for suspected nasopharyngeal carcinoma, outperforming conventional EBV serologies in outpatient practice.
P85-Ab, an anti-EBV BNLF2b antibody test, showed excellent accuracy for suspected nasopharyngeal carcinoma and outperformed older EBV markers in most outpatient settings.
A large shotgun metagenomic study links gut dysbiosis to EBV-associated nasopharyngeal carcinoma and shows that microbial markers, especially combined with EBV markers, may strengthen diagnosis and prognostic assessment.
Radiation-induced otitis media with effusion (RI-OME) shows heightened bacterial colonization with opportunistic pathogens. Although microbial presence predicts early recurrence (≤4 weeks post-tympanocentesis), it does not independently inf
This review analyzes the 5-year overall survival outcomes of the CAPTAIN-1st trial, establishing camrelizumab plus chemotherapy as a long-term standard of care for recurrent or metastatic nasopharyngeal carcinoma.
The 3-year follow-up of the RATIONALE-309 trial demonstrates that first-line tislelizumab plus chemotherapy significantly improves overall survival (45.3 months) in recurrent or metastatic nasopharyngeal carcinoma, identifying B-cell signat
Long-term results from the RATIONALE-309 trial show tislelizumab plus chemotherapy significantly improves survival in recurrent or metastatic nasopharyngeal carcinoma, establishing a durable therapeutic standard and identifying B-cell signa
A secondary analysis of the CAPTAIN-1st trial reveals that adding camrelizumab to first-line chemotherapy significantly improves five-year overall survival in RM-NPC, with a 37.8% survival rate and notable benefits linked to rapid EBV DNA c
A comprehensive case-control study published in The Lancet Regional Health – Americas highlights how Intensity-Modulated Proton Therapy (IMPT) significantly reduces toxicities and improves quality of life for nasopharyngeal carcinoma
A case-control study comparing IMPT and IMRT for nasopharyngeal carcinoma shows that IMPT significantly reduces grade 2+ acute toxicities without compromising long-term survival or local-regional control, suggesting a superior therapeutic i
Recent clinical trials reveal that LBL-007, a novel anti-LAG-3 antibody, significantly enhances treatment outcomes for advanced nasopharyngeal carcinoma when combined with PD-1 inhibitors, marking a potential shift in the standard of care f
A phase 3 randomized trial in China showed the EGFR/HER3 bispecific antibody‑drug conjugate izalontamab brengitecan produced a 54.6% objective response rate versus 27.0% with chemotherapy in heavily pretreated recurrent or metastatic nasoph
This phase 3 trial compares induction-concurrent chemotherapy with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma, finding no significant difference in 3-year progression-free survival while highlighting dis
A multicenter phase 3 trial demonstrates that sequential chemoradiotherapy is noninferior to induction plus concurrent chemoradiotherapy for stage III/IVA nasopharyngeal carcinoma with fewer acute toxicities.
A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting
